Financial Performance - As of September 30, 2024, Traws Pharma had cash, cash equivalents, and short-term investments of approximately $5.4 million, down from $20.8 million at December 31, 2023[6]. - The net loss for Q3 2024 was $8.5 million, or $8.81 per share, compared to a net loss of $4.7 million, or $5.64 per share, for the same period in 2023[9]. - Traws Pharma's accumulated deficit increased to approximately $619.2 million as of September 30, 2024, compared to $482.6 million at the end of 2023[14]. - The company reported total liabilities of $10.97 million as of September 30, 2024, down from $12.01 million at the end of 2023[14]. Research and Development - Research and development (R&D) expenses for Q3 2024 totaled $5.1 million, compared to $2.5 million for the same period in 2023, reflecting a significant increase due to the initiation of Phase 1 studies[7]. - Traws Pharma is advancing its antiviral programs, with Phase 2 studies for ratutrelvir and tivoxavir marboxil expected to commence in 2025[2]. - Phase 1 data for ratutrelvir indicates it can be dosed without ritonavir, showing no treatment-related adverse events and consistent plasma drug levels[3]. - Phase 1 data for tivoxavir marboxil supports its potential as a single-dose treatment for influenza, maintaining plasma drug levels above the EC90 for over five days[4]. Operating Expenses - General and administrative (G&A) expenses for Q3 2024 were $3.5 million, up from $2.7 million in Q3 2023, primarily due to increased professional and consulting fees[8]. - Traws Pharma's total operating expenses for Q3 2024 were $8.6 million, compared to $5.1 million for the same period in 2023[15].
Traws Pharma, Inc.(TRAW) - 2024 Q3 - Quarterly Results